$NVAX & $PFE Today’s Research Reports on Stocks
Post# of 4481
(Total Views: 307)
Posted On: 04/13/2018 8:41:09 AM
$NVAX & $PFE Today’s Research Reports on Stocks to Watch: Novavax and Pfizer
NEW YORK, NY / ACCESSWIRE / April 13, 2018 / Novavax shares crumbled on Thursday after the company sold 30.3 million shares of common stock to the public at a lower price than what the stock closed on Tuesday. Shares of Pfizer saw gains after finalizing an agreement with Allogene and announcing that it has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926 for boys with Duchenne muscular dystrophy.
RDI Initiates Coverage on:
Novavax, Inc.
https://rdinvesting.com/news/?ticker=NVAX
Pfizer Inc.
https://rdinvesting.com/news/?ticker=PFE
Novavax, Inc. shares closed down 12.98% yesterday and continued to see more losses in after-hours trading after Wall Street digested the news that the company had sold 30.3 million shares of common stock to the public at a price of $1.65 per share. Considering that shares closed at $2.08 a share on Wednesday, the $1.65 price was a big discount. According to the company, the proceeds from the offering will be used for general corporate purposes. The offering is anticipated to close on or around April 16, 2018, subject to the satisfaction of customary closing conditions. Trading volume was significant for the stock yesterday at almost 39.5 million shares compared to an average trading volume of just under 10 million shares.
Access RDI's Novavax, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NVAX
Pfizer Inc. shares closed up 1.48% yesterday on nearly 22.6 million shares traded. Earlier this week the pharma giant announced that it finalized its agreement with Allogene Therapeutics for its allogeneic CAR-T therapy asset portfolio. It was earlier in the month on April 3rd that Pfizer announced it had entered the agreement to develop cancer therapies. As part of the agreement, Allogene has rights to Pfizer's 16- pre-clinical CAR-T assets from Cellectis and Servier and one clinical asset licensed from Servier, UCART19, an allogeneic CAR-T therapy that is being developed for treatment of CD19-expressing hematological malignancies. David Chang, M.D., Ph.D., the President and CEO of Allogene commented, "The completion of our agreement with Pfizer represents a bold undertaking by leaders in the field to expedite the development of the next wave of cancer immunotherapies." In other news, Pfizer also announced yesterday that it has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). CEO and Founder of Cure Duchenne, Debra Miller, stated, "On behalf of the community of individuals and families living with Duchenne muscular dystrophy, we applaud the important step Pfizer has taken to advance a potentially transformational treatment option for boys stricken with this terrible disease. The momentum we are seeing in the field of gene therapy emphasizes the maturing opportunity to advance the science. Today, there are very limited treatment options for our boys. Through collaboration and ongoing dialogue with companies like Pfizer, we hope to succeed in finding therapies that could dramatically change the outcomes for those with DMD."
Access RDI's Pfizer Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PFE
Our Actionable Research on Novavax, Inc. (NASDAQ: NVAX) and Pfizer Inc. (NYSE: PFE) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.NEW YORK, NY / ACCESSWIRE / April 13, 2018 / Novavax shares crumbled on Thursday after the company sold 30.3 million shares of common stock to the public at a lower price than what the stock closed on Tuesday. Shares of Pfizer saw gains after finalizing an agreement with Allogene and announcing that it has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926 for boys with Duchenne muscular dystrophy.
RDI Initiates Coverage on:
Novavax, Inc.
https://rdinvesting.com/news/?ticker=NVAX
Pfizer Inc.
https://rdinvesting.com/news/?ticker=PFE
Novavax, Inc. shares closed down 12.98% yesterday and continued to see more losses in after-hours trading after Wall Street digested the news that the company had sold 30.3 million shares of common stock to the public at a price of $1.65 per share. Considering that shares closed at $2.08 a share on Wednesday, the $1.65 price was a big discount. According to the company, the proceeds from the offering will be used for general corporate purposes. The offering is anticipated to close on or around April 16, 2018, subject to the satisfaction of customary closing conditions. Trading volume was significant for the stock yesterday at almost 39.5 million shares compared to an average trading volume of just under 10 million shares.
Access RDI's Novavax, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NVAX
Pfizer Inc. shares closed up 1.48% yesterday on nearly 22.6 million shares traded. Earlier this week the pharma giant announced that it finalized its agreement with Allogene Therapeutics for its allogeneic CAR-T therapy asset portfolio. It was earlier in the month on April 3rd that Pfizer announced it had entered the agreement to develop cancer therapies. As part of the agreement, Allogene has rights to Pfizer's 16- pre-clinical CAR-T assets from Cellectis and Servier and one clinical asset licensed from Servier, UCART19, an allogeneic CAR-T therapy that is being developed for treatment of CD19-expressing hematological malignancies. David Chang, M.D., Ph.D., the President and CEO of Allogene commented, "The completion of our agreement with Pfizer represents a bold undertaking by leaders in the field to expedite the development of the next wave of cancer immunotherapies." In other news, Pfizer also announced yesterday that it has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). CEO and Founder of Cure Duchenne, Debra Miller, stated, "On behalf of the community of individuals and families living with Duchenne muscular dystrophy, we applaud the important step Pfizer has taken to advance a potentially transformational treatment option for boys stricken with this terrible disease. The momentum we are seeing in the field of gene therapy emphasizes the maturing opportunity to advance the science. Today, there are very limited treatment options for our boys. Through collaboration and ongoing dialogue with companies like Pfizer, we hope to succeed in finding therapies that could dramatically change the outcomes for those with DMD."
Access RDI's Pfizer Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PFE
Our Actionable Research on Novavax, Inc. (NASDAQ: NVAX) and Pfizer Inc. (NYSE: PFE) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
NEW YORK, NY / ACCESSWIRE / April 13, 2018 / Novavax shares crumbled on Thursday after the company sold 30.3 million shares of common stock to the public at a lower price than what the stock closed on Tuesday. Shares of Pfizer saw gains after finalizing an agreement with Allogene and announcing that it has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926 for boys with Duchenne muscular dystrophy.
RDI Initiates Coverage on:
Novavax, Inc.
https://rdinvesting.com/news/?ticker=NVAX
Pfizer Inc.
https://rdinvesting.com/news/?ticker=PFE
Novavax, Inc. shares closed down 12.98% yesterday and continued to see more losses in after-hours trading after Wall Street digested the news that the company had sold 30.3 million shares of common stock to the public at a price of $1.65 per share. Considering that shares closed at $2.08 a share on Wednesday, the $1.65 price was a big discount. According to the company, the proceeds from the offering will be used for general corporate purposes. The offering is anticipated to close on or around April 16, 2018, subject to the satisfaction of customary closing conditions. Trading volume was significant for the stock yesterday at almost 39.5 million shares compared to an average trading volume of just under 10 million shares.
Access RDI's Novavax, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NVAX
Pfizer Inc. shares closed up 1.48% yesterday on nearly 22.6 million shares traded. Earlier this week the pharma giant announced that it finalized its agreement with Allogene Therapeutics for its allogeneic CAR-T therapy asset portfolio. It was earlier in the month on April 3rd that Pfizer announced it had entered the agreement to develop cancer therapies. As part of the agreement, Allogene has rights to Pfizer's 16- pre-clinical CAR-T assets from Cellectis and Servier and one clinical asset licensed from Servier, UCART19, an allogeneic CAR-T therapy that is being developed for treatment of CD19-expressing hematological malignancies. David Chang, M.D., Ph.D., the President and CEO of Allogene commented, "The completion of our agreement with Pfizer represents a bold undertaking by leaders in the field to expedite the development of the next wave of cancer immunotherapies." In other news, Pfizer also announced yesterday that it has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). CEO and Founder of Cure Duchenne, Debra Miller, stated, "On behalf of the community of individuals and families living with Duchenne muscular dystrophy, we applaud the important step Pfizer has taken to advance a potentially transformational treatment option for boys stricken with this terrible disease. The momentum we are seeing in the field of gene therapy emphasizes the maturing opportunity to advance the science. Today, there are very limited treatment options for our boys. Through collaboration and ongoing dialogue with companies like Pfizer, we hope to succeed in finding therapies that could dramatically change the outcomes for those with DMD."
Access RDI's Pfizer Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PFE
Our Actionable Research on Novavax, Inc. (NASDAQ: NVAX) and Pfizer Inc. (NYSE: PFE) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.NEW YORK, NY / ACCESSWIRE / April 13, 2018 / Novavax shares crumbled on Thursday after the company sold 30.3 million shares of common stock to the public at a lower price than what the stock closed on Tuesday. Shares of Pfizer saw gains after finalizing an agreement with Allogene and announcing that it has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926 for boys with Duchenne muscular dystrophy.
RDI Initiates Coverage on:
Novavax, Inc.
https://rdinvesting.com/news/?ticker=NVAX
Pfizer Inc.
https://rdinvesting.com/news/?ticker=PFE
Novavax, Inc. shares closed down 12.98% yesterday and continued to see more losses in after-hours trading after Wall Street digested the news that the company had sold 30.3 million shares of common stock to the public at a price of $1.65 per share. Considering that shares closed at $2.08 a share on Wednesday, the $1.65 price was a big discount. According to the company, the proceeds from the offering will be used for general corporate purposes. The offering is anticipated to close on or around April 16, 2018, subject to the satisfaction of customary closing conditions. Trading volume was significant for the stock yesterday at almost 39.5 million shares compared to an average trading volume of just under 10 million shares.
Access RDI's Novavax, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NVAX
Pfizer Inc. shares closed up 1.48% yesterday on nearly 22.6 million shares traded. Earlier this week the pharma giant announced that it finalized its agreement with Allogene Therapeutics for its allogeneic CAR-T therapy asset portfolio. It was earlier in the month on April 3rd that Pfizer announced it had entered the agreement to develop cancer therapies. As part of the agreement, Allogene has rights to Pfizer's 16- pre-clinical CAR-T assets from Cellectis and Servier and one clinical asset licensed from Servier, UCART19, an allogeneic CAR-T therapy that is being developed for treatment of CD19-expressing hematological malignancies. David Chang, M.D., Ph.D., the President and CEO of Allogene commented, "The completion of our agreement with Pfizer represents a bold undertaking by leaders in the field to expedite the development of the next wave of cancer immunotherapies." In other news, Pfizer also announced yesterday that it has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). CEO and Founder of Cure Duchenne, Debra Miller, stated, "On behalf of the community of individuals and families living with Duchenne muscular dystrophy, we applaud the important step Pfizer has taken to advance a potentially transformational treatment option for boys stricken with this terrible disease. The momentum we are seeing in the field of gene therapy emphasizes the maturing opportunity to advance the science. Today, there are very limited treatment options for our boys. Through collaboration and ongoing dialogue with companies like Pfizer, we hope to succeed in finding therapies that could dramatically change the outcomes for those with DMD."
Access RDI's Pfizer Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PFE
Our Actionable Research on Novavax, Inc. (NASDAQ: NVAX) and Pfizer Inc. (NYSE: PFE) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
(1)
(0) Engineer by trade & Swing Trader at Heart!
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
Scroll down for more posts ▼